Skip to main content

Table 1 Patient clinical and laboratory characteristics during follow up

From: Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study

 

At

baseline

(n = 25)

At 1

month *

(n = 25)

At 3

months **

(n = 24)

At 6

months

(n = 20)

At 12

months

(n = 18)

At latest follow up

(n = 15)

Fever

24 (96)

1 (4)

1 (4)

2 (10)

0

0

Rash

16 (64)

0

0

1 (5)

0

0

Lymphadenopathy

14 (56)

0

0

1 (5)

0

0

Arthralgias

22 (88)

9 (36)

5 (21)

2 (10)

0

0

TJC

12 (0-38)

0 (0-24)

0 (0-24)

0 (0-34)

NA ***

NA ***

Arthritis

15 (60)

2 (8)

2 (8)

2 (10)

0

0

SJC

1 (0-15)

0 (0-5)

0 (0-5)

0 (0-34)

NA ***

NA ***

Hepatosplenomegaly

11 (44)

0

0

1 (5)

0

0

Sore throat

14 (56)

1 (4)

1 (4)

1 (5)

0

0

Serositis

5 (20)

0

0

0

0

0

Anemia ‡

(Hb < 12 g/dl for females and < 13.5 g/dl for males)

16 (64)

10 (40)

5 (21)

2 (10)

0

0

Hb (g/dl)

11.8 (8.5-14.4)

12.7 (8.7-16)

13.1 (9.8-15.3)

14 (10-16)

13.7 (12-15.8)

14 (12.3-15.4)

Leucocytosis

(> 10,000/mm3)

21 (84)

9 (36)

5 (21)

3 (15)

0

0

WBC (× 103/mm3)

16.8 (4.8-33.6)

8.2 (3-20.6)

6.9 (2.8-15)

6.5 (3.5-18.4)

6.3 (3.2-9.8)

6.5 (4-9)

Thrombocytosis

(> 450,000/mm3)

8 (32)

3 (12)

2 (8)

1 (5)

0

0

PLTs (× 103/mm3)

378 (134-554)

228 (156-555)

251 (160-556)

215 (165-511)

236 (145-334)

210 (121-274)

Elevated CRP (> 10 mg/dl)

25 (100)

8 (32)

6 (25)

4 (20)

0

0

CRP (mg/dl)

111 (19-318)

5.4 (0.1-200)

6 (0.2-107)

3.6 (0.8-119)

2 (0.1-10)

3.5 (0.4-9)

Elevated ESR (> 30 mm/h)

24 (96)

6 (24)

2 (8)

1 (5)

0

0

ESR (mm/h)

75 (26-120)

20 (2-130)

11.5 (2-72)

10 (2-105)

6 (2-23)

4 (1-15)

High ferritin levels (> 300 ng/ml)

24 (96)

7 (28)

4 (17)

3 (15)

0

0

Ferritin (ng/ml)

3000 (192-88126)

217 (47-6413)

111 (24-7700)

165 (9-3163)

59 (10-209)

58 (41-124)

Elevated liver enzymes

15 (60)

6 (24)

1 (4)

2 (10)

2 (11)

0

HAQ

2.19 (0.25-3)

0.31 (0-2.25)

0 (0-1.44)

0 (0-3)

0 (0-1.25)

0 (0-1.25)

VAS pain

2.4 (0.6-3)

0 (0-2.4)

0 (0-2.7)

0 (0-2.7)

0 (0-1.5)

0 (0-1.5)

VAS global

2.25 (0.9-3)

0.3 (0-2.4)

0 (0-2.7)

0 (0-2.7)

0 (0-1.5)

0 (0-1.5)

VAS physician

1.8 (0.9-2.7)

0.3 (0-1.8)

0 (0-2.4)

0 (0-2.4)

0 (0-0.3)

0 (0-0.3)

ACR20

NA ***

18/22 (82)

17/21 (81)

15/17 (88)

15/15 (100)

13/13 (100)

ACR50

NA ***

15/22 (68)

16/21 (76)

15/17 (88)

14/15 (93)

13/13 (100)

ACR70

NA ***

14/22 (64)

15/21 (71)

13/17 (76)

13/15 (87)

12/13 (92)

Methylprednisolone oral dose † (mg/d)

18 (0-48)

14 (0-40)

8 (0-32)

7 (0-24)

0.5 (0-14)

0 (0-8)

  1. * Significant comparisons of clinical and laboratory parameters at one month vs. baseline: fever P < 0.001, rash P < 0.001, lymphadenopathy P < 0.001, arthralgias P < 0.001, TJC P < 0.001, arthritis P < 0.001, SJC P = 0.01, hepatosplenomegaly P = 0.002, sore throat P < 0.001, serositis P = 0.063, Hb (g/dl) 0.007, leucocytosis P = 0.001, WBC (× 103/mm3) P < 0.001, thrombocytopenia P = 0.063, PLTs (× 103/mm3) P = 0.03, elevated CRP P < 0.001, CRP (mg/dl) P = 0.001, elevated ESR P < 0.001, ESR (mm/h) P = 0.013, high ferritin levels P = 0.004, ferritin (ng/ml) P = 0.002, elevated liver enzymes P = 0.021, HAQ score P < 0.001, VAS pain score P < 0.001, VAS global score P < 0.001, VAS physician score P < 0.001.
  2. ‡ Anemia at one month vs. baseline P = 0.375, at three months vs. baseline P = 0.008.
  3. ** Significant comparisons at three months vs. one month: CRP (mg/dl) P = 0.028, ESR (mm/h) P = 0.04, Hb (g/dl) P = 0.042.
  4. † Significant reduction of the oral methylprednisolone dose during follow-up: at one month vs. baseline P = 0.001, at three months vs. one month P = 0.001, at six months vs. three months P = 0.015, at 12 months vs. six months P = 0.005, at end vs. 12 months P = 0.043.
  5. *** NA, not applicable
  6. ACR, American College of Rheumatology; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; Hb, hemoglobin; PLTs, platelets; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale; WBC, white blood cells.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us